Clinical Study of the Therapeutic Effectiveness of In-silico-Designed, Machine Learning Inspired, and Quantum-molecularly Coupled Personalized Neoantigenic Vaccines Microlyvaq™ in Patients With Advanced Non-small Cell Lung Cancer

Clinical trial NCT07285434 · ENROLLING_BY_INVITATION

Trial details

NCT number: NCT07285434
Sponsor: Biogenea Pharmaceuticals Ltd.
Status: ENROLLING_BY_INVITATION
Phase: Early Phase 1
Study type: INTERVENTIONAL

NSCLC (Non-small Cell Lung Cancer)Squamous Lung Cancer With FGFR1 Amplification Non-Squamous Non Small Cell Lung Cancer

Start date: 2026-02-02
Primary completion: 2028-02-02
Enrollment: 90

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.